RxDoctor Payments Data

Andrew Taylor, MD

Neurology · Foxboro, MANPI 1467870972

Payments from drug & device makers

$55,028in general payments, 2019–2025

Across 494 payments — averaging $111.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$21K
  • UCB SA$17K
  • E.r. Squibb & Sons, L.L.C.$7K
  • AstraZeneca$1K
  • SK Life Science, Inc.$1K
  • AbbVie$807
  • plus $7K from 54 others

What the payments were for

  • Speaking & faculty fees$9299%
  • Food & beverage$9,28190%
  • Education$1131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bristol Myers Squibb11$21,216
UCB SA2$17,000
E.r. Squibb & Sons, L.L.C.4$6,728
AstraZeneca(2 entities)30$1,425
SK Life Science, Inc.41$1,109
AbbVie(2 entities)45$807
Lundbeck LLC36$796
Novartis28$528
CSL Behring22$516
Pfizer47$479
EMD Serono, Inc.20$472
Teva Pharmaceuticals USA, Inc.13$269
Alnylam Pharmaceuticals Inc.12$254
Biogen14$254
Mallinckrodt Hospital Products Inc.11$227
Amgen(2 entities)12$226
Eisai Inc.10$178
UCB, Inc.8$167
Amneal Pharmaceuticals LLC10$151
Catalyst Pharmaceuticals, Inc.7$147
Xeris Pharmaceuticals, Inc.8$145
Tanabe Pharma America, Inc.8$134
Biohaven Pharmaceuticals, Inc.9$111
EDW Pharma, Inc.1$108
Lilly USA, LLC6$104
Neurocrine Biosciences, Inc.5$88
Averitas Pharma Inc.4$88
TG Therapeutics, Inc.4$84
Acorda Therapeutics, Inc4$75
Otsuka America Pharmaceutical, Inc.3$64
Argenx US, Inc.3$64
Kedrion Biopharma, Inc.3$63
GE HealthCare7$56
Medtronic2$51
Johnson & Johnson(2 entities)2$49
Avanir Pharmaceuticals, Inc.2$48
Acadia Pharmaceuticals Inc2$48
Neuropace, Inc.2$46
Almatica Pharma LLC2$42
ANI Pharmaceuticals, Inc.2$41
Amylyx Pharmaceuticals, Inc.2$40
Biohaven Pharmaceutical Holding Company Ltd.2$38
Merz Pharmaceuticals, LLC2$37
Livanova USA, Inc.2$36
Genentech USA, Inc.2$35
Grifols USA, LLC2$35
Impel Pharmaceuticals Inc.2$35
Greenwich Biosciences, Inc.2$28
Octapharma USA, Inc.1$27
Arbor Pharmaceuticals, Inc.1$23
Sanofi1$22
MDD US Operations, LLC1$21
GRT US Holding, Inc.1$20
Supernus Pharmaceuticals, Inc.1$18
Axsome Therapeutics, Inc.1$18
Mylan Specialty L.p.1$17
Takeda Pharmaceuticals U.S.A., Inc.1$17
Adamas Pharmaceuticals, Inc.1$17
Avion Pharmaceuticals1$15
Merz North America, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,028 in reported general payments places this provider in the 75th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$127,802
Medicare patients
480
Services billed
1,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FirdapseAmifampridine Phosphate12$686,938
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5059$408,142
EvrysdiRisdiplam11$302,478
Radicava OrsEdaravone13$184,184
Nurtec OdtRimegepant Sulfate56$103,790
Emgality PenGalcanezumab-Gnlm75$59,121
UbrelvyUbrogepant33$38,569
QuliptaAtogepant34$37,341
Emgality SyringeGalcanezumab-Gnlm15$35,488
Aimovig AutoinjectorErenumab-Aooe22$16,654
Gabapentin583$11,385
Ajovy SyringeFremanezumab-Vfrm13$9,277
Pregabalin191$4,438
Lamotrigine ErLamotrigine13$3,703
Duloxetine Hcl159$3,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Catalyst Pharmaceuticals, Inc.Firdapse$147$686,93812 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$17$408,14259 claims
Genentech USA, Inc.Evrysdi$35$302,47811 claims
PfizerNurtec Odt$479$103,79056 claims
AbbVieUbrelvy, Qulipta$807$75,91167 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$151$2,44922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 761 neurology providers in Massachusetts.

Other neurology in Foxboro

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →